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Objective: Evaluation of the efﬁcacy and safety of a single oral dose of a 1200 mg sachet of chondroitin
4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400) (equivalence
study) and vs placebo (superiority study) during 3 months, in patients with knee osteoarthritis (OA).
Design: Comparative, double-blind, randomized, multicenter study, including 353 patients of both
genders over 45 years with knee OA. Minimum inclusion criteria were a Lequesne index (LI)  7 and
pain  40 mm on a visual analogue scale (VAS). LI and VAS were assessed at baseline and after
1e3 months. Equivalence between CS was tested using the per-protocol procedure and superiority of CS
vs placebo was tested using an intent-to-treat procedure.
Results: After 3 months of follow-up, no signiﬁcant difference was demonstrated between the oral daily
single dose of CS 1200 formulation and the three daily capsules of CS 400. Patients treated with CS 1200
or CS 3*400 were signiﬁcantly improved compared to placebo after 3 months of follow-up in terms of LI
(<0.001) and VAS (P < 0.01). No signiﬁcant difference in terms of security and tolerability was observed
between the three groups.
Conclusion: This study suggests that a daily administration of an oral sachet of 1200 mg of chondroitin
4&6 sulfate allows a signiﬁcant clinical improvement compared to a placebo, and a similar improvement
when compared to a regimen of three daily capsules of 400 mg of the same active ingredient.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis and is
a leading cause of morbidity and disability1. Treatment strategies
for OA include both non-pharmacological and pharmacological
therapies. Among pharmacological therapies, analgesics and non-
steroidal anti-inﬂammatory drugs (NSAIDs) are current treatment
options for OA because of their well-established efﬁcacy2,3.
However, long-term use of these drugs can induce a number of
potentially serious side effects, particularly in the elderly. For this
reason, attention has recently been focused on the investigation
and development of new types of drugs and treatments that can: J.Y. Reginster, University of
Health Economics, CHU Sart-
25-81; Fax: 32-4-366-28-12.
Zegels), jyreginster@ulg.ac.be
s Research Society International. Pimprove the clinical symptoms of OA with better tolerability and
safety proﬁles, such as symptomatic slow-acting drugs for OA
(SYSADOAs)4.
Chondroitin sulfate (CS) consists of repeating chains of glycos-
aminoglycans. It is a major component of cartilage, providing
structure, holding water and nutrients and allowing other mole-
cules to move through the cartilage providing resistance and
elasticity to the cartilage5,6. It has been shown, in numerous short-
and long-term double-blind clinical trials, to relieve pain and
increase joint function and, to slow down progression of the
disease7e12.
CHONDROSULF (Laboratoire Genevrier), a CS preparation that
has been approved as a prescription drug, is marketed in several
foreign countries under several forms (i.e., capsules, tablets and
granules). The prescribed dosage, in France, is three intakes/day,
corresponding to 1200 mg of active ingredient. Some patients
might be interested in receiving a pharmaceutical form which
allows the absorption of such a dose in a single daily intake, thusublished by Elsevier Ltd. All rights reserved.
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reasons, the new dosage of 1200 mg/day needs a new pharma-
ceutical form, i.e., a 1200 mg CS oral gel sachet.
The objective of this phase III clinical trial was to assess the
efﬁcacy of a single daily intake of CHONDROSULF 1200mg oral gel
sachet (CS 1200) vs CHONDROSULF 400mg three capsules/day (CS
3*400) vs placebo sachet or capsules during 3 months. The primary
objective of this clinical trial was to conﬁrm the equivalence of the
efﬁcacy of CS 1200 and of CS 3*400, compared to placebo. The
secondary objectivewas to compare the equivalence of the safety of
CS 1200, CS 3*400 and placebo.
Material and methods
Study design and patients selection
This study is a multicentre, comparative, randomized, double-
blind and double-dummy study. This study involved three
parallel treatment groups with an allocation ratio of 1:1:1. Group 1
was the CS 1200 receiving one oral gel sachet of CS 1200 mg/day &
one oral placebo capsule three times a day. Group 2 was the CS
3*400 receiving one oral placebo gel sachet/day & one oral capsule
of CS 400 mg three times a day. Group 3 was the control group
receiving one oral placebo gel sachet/day & one oral placebo capsule
three times a day. All placebos were identical in form and appear-
ance to the real drugs. The three different types of treatment were
allocated according to a randomisation list balanced/blocks of three
established by the sponsor with a randomisation method starting
from a validated SAS software. Treatment was allocated in
ascending order as recruitment proceeded, by assigning the ﬁrst
available number. All these drug supplies were provided by the
Institut Biochimique SA (IBSA)/Laboratoires Genévrier. No changes
to methods after trial commencement have to be reported. This
study was registered under the number EUDRACT 2005-005163-29
and was performed in compliance with the Helsinki Declaration.
The study group comprised patients from 10 centres in Belgium,
three in France and two in Switzerland. The sponsor of the study
delivered envelope to the investigators of these centres, who
enrolled and assigned participants to interventions. The main
inclusion criteria were outpatient status, aged over 45 years old
with primary knee OA diagnosed according to the clinical and
radiographic criteria of the American College of Rheumatology13.
The symptomatic target knee should have a pain score of at least
40 mm on a 0e100 mm visual analogue scale (VAS) and a score  7
at the Lequesne index (LI). If both knees were symptomatic, the
target knee was the most symptomatic knee.
The major exclusion criteria were destructive OA of the knee
justifying a surgery in the following 6months, important genu varum
or valgum >8, knee joint surgery in the last 3 months, viscosup-
plementation, tidal lavage in the last 6 months, arthritis and meta-
bolic arthropathies, Paget’s illness, having consumed basic treatment
of arthritis with SYSADOA (CSs, glucosamine sulfates, diacerein,
hyaluronic acid) in the last 3 months and corticoids during the last
month, presenting serious organic diseases (e.g., heart failure, renal
or hepatic insufﬁciency, blood dyscrasia, serious infection), psychi-
atric illness hindering the protocol compliance, alcoholism, pregnant
or likely to become it during clinical trial or lactating.
The only analgesic allowed during the study was paracetamol
500 mg, with a maximum consumption of 4 g a day (eight tablets/
day). This treatment had to be stopped at least 10 h before every
visit in order to ensure paracetamol elimination and thus to get the
most accurate pain and functional discomfort evaluation.
The study was approved by the ethics committee of all partici-
pating study centres. All patients gave their written informed
consent to participate.Outcomes assessment
Clinical assessments of the patients were performed at the
baseline and after a follow-up of 1e3 months.
The primary outcome measurement was the algo-functional
LI14,15. This index consists of a 10-item investigator-administered
questionnaire, which allows patients to rate pain or discomfort,
stiffness, difﬁculty performing daily activities and their maximum
walking capacity. The total score varies from 0 (no functional
consequence) to 24 (major disability).
Global spontaneous pain was measured on a vertical VAS of
100 mm where zero ¼ absent pain, and 100 ¼ maximum pain.
Consumption of paracetamol was recorded by the patient in a diary
on a daily basis. The global efﬁcacy assessment of the treatment
was estimated, at each visit, by both the patient and the investi-
gator, on a verbal semi quantitative four-point scale evaluation after
1e3 months of follow-up.
Treatment compliance was checked at each visit by counting the
sachets and capsules. The compliance was considered as:
 excellent: no day of missed treatment,
 good: <3 days of missed treatment,
 fair: from 3 to 7 days of missed treatment,
 poor: >7 days of missed treatment.
Any adverse event and abnormal results of routine laboratory
tests were reported. A serious adverse event was deﬁned as an
adverse event or reaction which could lead to death or is likely to
jeopardize the life of the person participating in the study, required
a hospitalization or the prolongation of hospitalization, caused an
important or lasting inability or a disability, or led to a congenital
anomaly or malformation, whatever the dose administered.
Statistical analysis
The equivalence test was decided a priori and has been per-
formed on the evolution of the LI between baseline and 3 months.
The equivalence conclusion has been based on the comparison of
the two-sided 95% conﬁdence interval (CI) of the difference
between the two treatments CS 1200 and CS 3*400. If this two-
sided 95% CI was between the two equivalence threshold
(D and D), then the equivalence was demonstrated. If the lower
margin of the two-sided 95% CI was above the lower equivalence
margin, then the non-inferiority was demonstrated.
The averages of the LI variations were compared between
groups at every visit by an analysis of variance (or a rank test if
necessary) and the global evolution of this main criterion for
different visits was compared by means of a two-way analysis of
variance for repeated measures with two factors, time and treat-
ment (with measurement of the interaction time*treatment).
When a signiﬁcant difference was become evident for all the
groups, analysis of variance was completed with a test of Scheffé.
The same procedure was followed for the evaluation of the varia-
tion, of pain measured on the VAS and for the total consumption of
paracetamol. Patient’s and investigator’s assessments about
product efﬁcacy at different times were compared by means of the
c2 test. The analysis of variance for repeated measures was per-
formed taking into account the test multiplicity. The Scheffé’s test
was chosen in a view to analyse the origin of the global difference
underlined by the repeated measure analysis of variance.
The number of patients involved in this clinical trial had to be
sufﬁcient so that the absence of difference between both groups
taking CS could not be interpreted as due to a lack of test power
caused by low enrolments and so that the power of the test was
sufﬁcient to point out a difference between the two groups of
Table I
General clinical examination and algo-functional LI
All
subjects
CS 1200 CS 3*400 Placebo P-value
N ¼ 352 N ¼ 117 N ¼ 119 N ¼ 117
Age (years)
mean  SD
65.2  9.9 65.4  10.4 65.3  8.8 64.9  10.6 0.94
Male gender
N (%)
125 (35.4) 40 (34.2) 47 (39.5) 38 (32.5) 0.50
BMI (kg/m2)
mean  SD
28.6  5.3 28.8  5.2 28.4  4.4 28.6  6.1 0.80
Lequesne’s
score
(target knee)
mean  SD
11.4  3.0 11.9  3.1 11.2  2.6 11.2  3.2 0.13
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to determine the required minimum number of patients by group in
order to test equivalence, ensuring that this enrolment would be
sufﬁcient to show a difference between CS groups and the placebo
group. The sample size calculation was based on the results of
several previous studies. The medium reduction of the LI after
administration of CS for 3 months was 4.0 score points in a previous
clinical trial16, 2.8 score points in another clinical trial17, 2.9 score
points in a third clinical trial18, 5.4 in a fourth clinical trial19 and
4.6 score points in the ﬁfth trial20. The medium reduction on the ﬁve
studies was considered in the order of four score points and the
standard deviation (SD) of this evolution in the order of three. The
biggest acceptable difference as for equivalence between two groups
was ﬁxed, before the start of the study, to 1.0 score point of reduction
of the LI in 3 months, i.e., 25% of the medium reduction obtained in
the above-mentioned studies. The sample size calculation for
equivalence trials showed that 112 subjects/group in a per-protocol
(PP) analysis would ensure the equivalence between both formula-
tions, with an alpha risk of 5 % and an 80% power. Equivalence
between CS 1200 and CS 3*400 was tested using the PP procedure.
However, for superiority assessment between CS and placebo,
intent-to-treat (ITT) analyses were performed for all randomized
patients, using the last observation carried forward approach. It has
been veriﬁed by the use of the formula n ¼ s2=D22ðZ 1 aþ Z 1
bÞ that this sample size was sufﬁcient to show a difference of 1.5
score point with a 90% power and a difference of two points with
more than 95% power between the groups taking CS and the group
taking placebo, testing superiority at risk level of alpha ¼ 0.05.
Results
Out of 354 patients screened, 353 were randomly assigned to
receive CS 1200, CS 3*400 or placebo (Fig. 1). Less than 15% ofRandomized
Subjects (N=354) 
No data for main criterion 
Subject’s decision (N=1) 
Subjects receiving 
treatment (N=353) 
CS 1200 Group  
(N=117) 
CS 3*400 Group  
(N=119) 
Placebo Group 
(N=117)
Serious Adverse event 
(N=2)
Adverse event (N=0) 
Non compliance (N=1) 
Subject’s decision (N=6) 
Lost of follow up (N=1) 
Inclusion criteria deviation 
(N=3)
Serious adverse event 
(N=4) 
Adverse event (N=2) 
Error at inclusion (N=1) 
Non compliance (N=1) 
Subject’s decision (N=3) 
Lost of follow up (N=3) 
Intolerance (N=1) 
Serious adverse event 
(N=2) 
Adverse Event (N=4) 
Error at inclusion (N=1) 
Non compliance (N=2) 
Subject’s decision (N=3) 
Intolerance (N=3) 
Other’s decision (N=2) 
Completed study  
(N=104) 
Withdrawn (N=13) 
Completed study 
(N=104) 
Withdrawn (N=15) 
Completed study 
(N=100) 
Withdrawn (N=17) 
Fig. 1. Disposition of subjects.dropout patients were observed leading to a PP analysis of 308
subjects. The study started on March 2nd 2006 and ﬁnished on
April 9th 2008. Baseline characteristics of the studied population
are reported in Table I. No signiﬁcant differences appears between
the three groups with regard to demographic and baseline
characteristics.Primary outcomes
After 3 months of follow-up, no signiﬁcant difference was
demonstrated in PP analysis between the oral daily single dose of
CS 1200 and the three daily capsules of CS 400 in the algo-
functional LI. Indeed, as shown in Table II, the CI of the difference
between the average variation of the LI score under treatment with
CS 1200 and CS 3*400 is [0.81; 1.08]. The lower limit of this CI is
above the non-inferiority threshold 1 and leads to the conclusion
that CS 1200 is not inferior compared to CS 3*400.
Using the ITT procedure, the Scheffé test showed that CS 1200
and CS 3*400 are signiﬁcantly more effective than the control in
decreasing the algo-functional LI after the 3-month treatment
period (P¼ 0.0001) (Table III). In the CS groups, the reduction of the
LI was almost of 40% compared to baseline. Interestingly, all these
difference in LI between CS groups and placebo were already
statistically signiﬁcant after 2 months of follow-up (Table III).Secondary outcomes
Among secondary outcome assessment, the Scheffé test
showed a statistical signiﬁcant difference between the two study
treatment groups and the placebo group; i.e., CS 1200 and CS
3*400 are more effective than the control in decreasing the VAS
pain score (P ¼ 0.02) (Table IV). In the CS groups, the reduction of
VAS score was near to 45%. The total consumption of paracetamol
along the study treatment period was quite similar in the three
treatment groups. More speciﬁcally, the mean (SD) number of
capsules of paracetamol used was 75.3 (103.9) in the CS 1200, 70.2
(93.1) in the CS 3*400 and 73.5 (107.4) for the placebo (P ¼ 0.93Table II
Equivalence for the change in the total score of algo-functional index of Lequesne
between M0 and M3 (n ¼ 104 for CS 1200 and CS 3*400 and n ¼ 100 for placebo)
Comparison between the three
groups two by two
Delta t-test CI (95%) Equivalence
limit
Group CS 1200 e group CS 3*400
(main criteria)
0.13 [0.81; 1.08] [1; 1]
Group CS 1200 e placebo group 2.59 [1.68; 3.49] [1; 1]
Group CS 3*400 e placebo group 2.45 [1.54; 3.36] [1; 1]
Table III
Change in LI during the treatment period
LI score CS 1200 CS 3*400 Placebo P-value
between
groups
Scheffé
test
ITT N ¼ 117 N ¼ 119 N ¼ 117
Pre-treatment
(M0)
11.9  3.1 11.2  2.6 11.2  3.2
Follow-up (M1) 9.8  3.7 9.4  3.1 10.1  3.7 0.32
Follow-up (M2) 8.4  3.8 8.4  3.6 9.9  4.3 0.003 (1, 2 s 3)
Final visit (M3) 7.8  4.2 7.5  3.9 9.7  4.6 0.0001 (1, 2 s 3)
Table V
Global compliance
All subjects CS 1200 CS 3*400 Placebo P-value
N ¼ 175 N ¼ 63 N ¼ 61 N ¼ 51
Poor 5.1% 1.6% 6.6% 7.8% 0.20
Fair 7.4% 9.5% 11.5% 0%
Good 8.6% 9.5% 6.6% 9.8%
Excellent 78.9% 79.4% 75.4% 82.4%
N ¼ number of subjects.
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a statistical difference between CS 1200 and CS 3*400. However,
a signiﬁcant superiority was observed in both CS groups compared
to placebo after 2 and 3 months, when evaluated by patients or by
investigators (all P < 0.05). Global compliance was comparable
between the three treatment groups along the treatment period
(Table V).
Safety
A total number of 260 adverse events were reported in 161
subjects during the study. The CS 1200 group reported 26.4% of
adverse events related to the treatment, the CS 3*400 group re-
ported 26.0% and the placebo group 41.7%. Eight serious adverse
events, all related to hospitalization, occurred during the study:
two in the placebo arm (i.e., endourethral prostate resection,
surgery related to frequent angina and snoring), two in the CS 1200
group (i.e., cystitis, radical prostatectomy) and four in the CS 3*400
group (i.e., transient ischaemic attack, acute intermediate
syndrome, surgery on lumbar spinal stenosis, myocardial infrac-
tion). No statistically signiﬁcant difference was demonstrated
between the three treatment groups in the mean number of
adverse events or in the number of subjects in each group with at
least one adverse event.
Discussion
This study suggests that a daily administration of an oral sachet
of 1200 mg of chondroitin 4&6 sulfate allows a signiﬁcant clinical
improvement compared to a placebo, and a similar improvement
when compared to a regimen of three daily capsules of 400 mg of
the same active ingredient.
Chronic illness requiring ongoing pharmacotherapy, such as OA,
continues to challenge health care systems. Patient adherence to
(taking the correct dose at the appropriate times, as prescribed) and
persistence with (continuing with chronic medication over long
periods of time) medications become an important issue in efforts
to improve patient outcomes and decrease health care costs21.
Many physicians consider medication non-adherence to be one ofTable IV
Change in the global spontaneous pain during the treatment period
VAS score
(mm)
CS 1200 CS 3*400 Placebo P-value
between
groups
Scheffé
test
ITT N ¼ 117 N ¼ 119 N ¼ 117
Pre-treatment
(M0)
65.2  13.7 62.7  14.8 62.5  15.0
Follow-up (M1) 52.5  21.0 48.9  20.9 50.3  21.2 0.43
Follow-up (M2) 43.0  22.9 43.1  23.5 47.9  22.9 0.18
Final visit (M3) 39.4  24.2 38.8  25.5 47.1  24.8 0.02 (1, 2 s 3)the most serious problems facing current medical practice22.
Several studies have highlighted the potential tradeoffs between
efﬁcacy, days of missed medication, and adverse events21. Despite
the development of therapeutically optimal dosing regimens,
medication doses are not always taken correctly. Dosing is one of
several factors affecting patient adherence23. Reducing the
frequency of dosing has been shown to improve patient adherence
to medication regimens, across a variety of therapeutic classes. In
addition, several studies have shown that using single-dose regi-
mens improves patient adherence21,23. Once- or twice-daily regi-
mens are associated with better adherence than thrice-daily
regimens24,25. We could then expect that the once a day oral
sachet of 1200 mg of CS will improve patient’s compliance
compared to a regimen of three daily capsules of 400 mg of the
same active ingredient. However, a study designed for this purpose
is needed before ﬁnal conclusion.
This study also shows a signiﬁcantly better symptomatic
improvement with CS compared to placebo. This conﬁrms previous
studies showing that CS could be considered as a SYSADOA4 and
that CS could be a cost-effective treatment in patients with knee
OA26. A previous study has compared CS 1200, CS 3*400 and
placebo but not with the objective to assess the equivalence or the
non-inferiority of CS 1200 over CS 3*40016. This previous 3-month
study randomized 127 patients with mono or bilateral knee OA to
CS 1200, CS 3*400 or placebo. In the CS groups, the LI and VAS
showed a signiﬁcant reduction of clinical symptoms (P < 0.01 for
both parameters), while only a slight reductionwas observed in the
placebo group (P ¼ ns for LI and P < 0.05 for VAS).
Previous short- and long-term studies have demonstrated that
CS is fairly safe7,27. In the present study, no signiﬁcant clinical or
laboratory differences between the CS and placebo groups were
observed, showing a similar tolerance and tolerability.
The validity of the study is supported by the design (double
blind placebo controlled trial) and the relatively low dropout rate.
One limitation in this study is the use of a speciﬁc CS preparation
(Chondrosulf 400mg) that has been approved as a prescription
drug and therefore our results cannot be generalized to other CS
products. Another limitation is that we have no data on joint
structure, including Kellgren and Lawrence score or joint space
width assessment. At last, our study was limited to a 3-month
period.
In conclusion, this study shows the non-inferiority of CS
1200 mg once a day compared to CS 400 mg three times a day and
the superiority of CS over placebo during a 3 months period of
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